Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Sales (2016 - 2025)

ImmunityBio (IBRX) has disclosed Return on Sales for 12 consecutive years, with 1.62% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 622.0% to 1.62% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.1%, a 2495.0% increase, with the full-year FY2025 number at 3.1%, up 2495.0% from a year prior.
  • Return on Sales was 1.62% for Q4 2025 at ImmunityBio, up from 2.1% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 1.62% in Q4 2025 to a low of 7357.0% in Q1 2022.
  • A 5-year average of 1248.45% and a median of 451.42% in 2021 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: surged 1981033bps in 2021, then crashed -677800bps in 2022.
  • ImmunityBio's Return on Sales stood at 234.75% in 2021, then tumbled by -532bps to 1483.92% in 2022, then dropped by -13bps to 1679.24% in 2023, then soared by 100bps to 7.84% in 2024, then soared by 79bps to 1.62% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Return on Sales are 1.62% (Q4 2025), 2.1% (Q3 2025), and 3.5% (Q2 2025).